Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugs.

ABSTRACT: The development of clinically effective drugs that could complement existing vaccines is urgently needed to reduce the morbidity and mortality associated with COVID-19. Drug-metabolizing enzymes, membrane-associated drug transporters, and inflammatory responses can partly determine the safety and efficacy of COVID-19 drugs by controlling their concentrations in both the systemic circulation and in peripheral tissues. It is still unknown how these factors affect how well COVID-19 drugs work in the clinic. We explore how drug metabolism and transport, as well as SARS-CoV-2-associated inflammatory response at disease target sites, may affect the clinical outcomes of COVID-19 drugs. In addition, we provide expert opinion on potential strategies for overcoming the clinical pharmacology and path

SUBMITTER: Nwabufo CK 

PROVIDER: S-EPMC9510059 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature